The ECHDC1 Knockout A2780 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 human ovarian adenocarcinoma cell line, harboring a targeted disruption of the ECHDC1 gene. This gene encodes the mitochondrial enzyme ethylmalonyl-CoA decarboxylase, which catalyzes a critical step in fatty acid beta-oxidation and branched-chain amino acid catabolism. The polyclonal format provides a heterogeneous pool of edited cells that collectively represent diverse loss-of-function alleles, serving as a robust model for population-level metabolic studies without clonal selection bias.
The parental A2780 cell line, established from an untreated patient with ovarian adenocarcinoma, is a well-characterized epithelial model for high-grade serous ovarian cancer. It is widely employed as a platinum-sensitive reference line for investigating tumor biology, drug response mechanisms, and metabolic adaptations. A2780 cells retain key oncogenic features and are a standard platform for ovarian cancer research, including studies of chemoresistance and metabolic vulnerabilities.
ECHDC1 encodes ethylmalonyl-CoA decarboxylase, which converts ethylmalonyl-CoA to butyryl-CoA in the mitochondrial matrix, linking odd-chain fatty acid oxidation and branched-chain amino acid degradation to the TCA cycle via acetyl-CoA production. The enzyme is regulated by metabolic sensors such as the nuclear receptor PPARA, the deacetylase SIRT1, and the coactivator PGC-1??. Within the beta-oxidation machinery, ECHDC1 interacts with electron transfer flavoprotein beta (ETFB), enoyl-CoA hydratase short chain 1 (ECHS1), and short/branched-chain acyl-CoA dehydrogenase (ACADSB). Disruption of ECHDC1 perturbs this metabolic node, leading to accumulation of ethylmalonyl-CoA and impaired flux through valine, leucine, and isoleucine degradation pathways, with potential downstream effects on mitochondrial acetyl-CoA pools and anaplerosis.
In A2780 ovarian cancer cells, loss of ECHDC1 function may compromise mitochondrial fatty acid oxidation capacity, potentially forcing a metabolic switch toward glycolysis or glutaminolysis. This polyclonal knockout model enables investigation of how ovarian cancer cells adapt to impaired lipid catabolism and may uncover synthetic lethal interactions or metabolic addictions relevant to therapeutic targeting. Given that aberrant fatty acid metabolism is recognized in ovarian tumor progression, the ECHDC1 knockout A2780 cells provide a physiologically relevant context to explore the intersection of lipid metabolism and ovarian cancer pathology.
Researchers can apply this ECHDC1 knockout polyclonal population in a range of metabolic assays, including radiometric or fluorometric fatty acid oxidation assays, Seahorse metabolic flux analysis to assess mitochondrial respiration and glycolytic capacity, and liquid chromatography-mass spectrometry (LC-MS)-based metabolite profiling to quantify ethylmalonyl-CoA and TCA cycle intermediates. Additionally, the cells are suitable for RT-qPCR and Western blot validation of metabolic gene and protein expression changes. Drug screening for metabolic disorders or cancer metabolism modulators is also feasible using this model. For further information or to discuss custom applications, please contact Ascent Research.
